Systematic comparison of machine learning methods for brain tumor classification, highlighting few-shot learning effectiveness.
Accurate brain tumor classification from MRI is often constrained by limited labeled data. We systematically compare conventional machine learning, deep learning, and few-shot learning (FSL) for four classes (glioma, meningioma, pituitary, no tumor) using a standardized pipeline. Models are trained on the Kaggle Brain Tumor MRI Dataset and evaluated across dataset regimes (100%→10%). We further test generalization on BraTS and quantify robustness to resolution changes, acquisition noise, and modality shift (T1→FLAIR). To support clinical trust, we add visual explanations (Grad-CAM/saliency) and report per-class results (confusion matrices). A fairness-aligned protocol (shared splits, optimizer, early stopping) and a complexity analysis (parameters/FLOPs) enable balanced comparison. With full data, Convolutional Neural Networks (CNNs)/Residual Networks (ResNets) perform strongly but degrade with 10% data; Model-Agnostic Meta-Learning (MAML) retains competitive performance (AUC-ROC ≥ 0.9595 at 10%). Under cross-dataset validation (BraTS), FSL—particularly MAML—shows smaller performance drops than CNN/ResNet. Variability tests reveal FSL’s relative robustness to down-resolution and noise, although modality shift remains challenging for all models. Interpretability maps confirm correct activations on tumor regions in true positives and explain systematic errors (e.g., “no tumor”→pituitary). Conclusion: FSL provides accurate, data-efficient, and comparatively robust tumor classification under distribution shift. The added per-class analysis, interpretability, and complexity metrics strengthen clinical relevance and transparency.
No takes yet. Share an insight, caveat, or question.
Vaidya et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: